Credit Suisse analyst Vamil Divan maintained a Hold rating on Bristol Myers (BMY) yesterday and set a price target of $59. The company’s shares closed on Friday at $49.89.
According to TipRanks.com, Divan ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.6% and a 40.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Johnson & Johnson.
Bristol Myers has an analyst consensus of Moderate Buy, with a price target consensus of $56.50, which is a 13.2% upside from current levels. In a report issued on January 25, Merrill Lynch also maintained a Hold rating on the stock with a $53 price target.
See today’s analyst top recommended stocks >>
Based on Bristol Myers’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.97 billion and net profit of $1.19 billion. In comparison, last year the company earned revenue of $5.45 billion and had a GAAP net loss of $2.33 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
